Document Detail

Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study.
MedLine Citation:
PMID:  15928633     Owner:  NLM     Status:  MEDLINE    
In this prospective, open-label pilot study, we evaluated the safety and efficacy of etanercept, a TNF-alpha inhibitor, in the treatment of moderate to severe alopecia areata, alopecia totalis, or alopecia universalis. Seventeen otherwise healthy adults with moderate to severe alopecia areata were enrolled. The primary outcome measure was the extent of hair regrowth during and after the end of treatment as evaluated by the Severity of Alopecia Tool (the SALT score). After between 8 and 24 weeks of continuous treatment with etanercept 50 mg given subcutaneously twice weekly, significant regrowth of hair was not shown in any of the subjects treated. Based on these results, etanercept appears to be ineffective in treating subjects with treatment-refractory, moderate to severe alopecia areata, alopecia totalis, or alopecia universalis.
Bruce E Strober; Kimberly Siu; Andrew F Alexis; Gene Kim; Ken Washenik; Animesh Sinha; Jerome L Shupack
Related Documents :
2326363 - Congenital skin fossae about the shoulder.
16078483 - Accumulation of explosives in hair.
11094213 - Spontaneous second trimester uterine rupture after classical cesarean.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  52     ISSN:  1097-6787     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-01     Completed Date:  2006-05-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1082-4     Citation Subset:  IM    
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alopecia Areata / drug therapy*
Immunoglobulin G / therapeutic use*
Middle Aged
Pilot Projects
Prospective Studies
Receptors, Tumor Necrosis Factor / therapeutic use*
Severity of Illness Index
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Performance of a rapid dermatology referral system during the anthrax outbreak.
Next Document:  Investigation of spinal pathology in notalgia paresthetica.